Gagnon Robert E.
Transaction: 07/23/2026
SELL
Change
-7,783
Price
$2.95
Filing
07/27/2026
Type
SELL
Opus Genetics, Inc.
IRD • Biotechnology
$3.99
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$444.51M
Growth
—
Cash Flow
1/5
Trend
Volatile
Evidence
Manageable debt level · 0Healthy liquidity · 6.43Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:56 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.99
Change0.00%
Shares Out111.38M
Market Cap$444.51M
Enterprise Value$390.63M
52W Range1.10 - 5.81
Beta0.58
P/E-4.13
P/S45.10
P/B-34.23
P/FCF-8.33
EV/Sales39.63
Price$3.99
Change0.00%
Shares Out111.38M
Market Cap$444.51M
Enterprise Value$390.63M
52W Range1.10 - 5.81
Beta0.58
P/E-4.13
P/S45.10
P/B-34.23
P/FCF-8.33
EV/Sales39.63
EV/EBITDA-7.18
EV/FCF-7.32
Earnings Yield-24.21%
FCF Yield-12.01%
Dividend Yield0.00%
Gross Margin100.00%
Oper. Margin-2.72%
Profit Margin-3.49%
Debt/Eq0.00
Current Ratio6.43
Quick Ratio6.43
Target$12.60
Target Upside215.73%
Target Median$10.00
Target Range8.00 - 20.00
Volume513.21K
Avg Volume941.45K
EPS Surprise-0.03
Investment DNA
How strong this company looks for long-term investors
30
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Manageable debt level · 0Healthy liquidity · 6.43Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 9 analyst votes · 2026-10-20
100/100
Bullish
Bullish
9
Hold
0
Bearish
0
Price Target
2026-08-14
Low
$8.00
Mean
$9.00
Median
$9.00
High
$10.00
Insider Transactions
Recent executive and insider activity
⚠ 1 high-volume insider sell detected
Magrath George
Transaction: 07/23/2026
SELL
Change
-9,475
Price
$2.95
Filing
07/27/2026
Type
SELL
SCHACHLE JOSEPH K
Transaction: 07/23/2026
SELL
Change
-4,644
Price
$2.94
Filing
07/27/2026
Type
SELL
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Gagnon Robert E. | SELL | -7,783 | $2.95 | 07/23/2026 | 07/27/2026 |
| Magrath George | SELL | -9,475 | $2.95 | 07/23/2026 | 07/27/2026 |
| SCHACHLE JOSEPH K | SELL | -4,644 | $2.94 | 07/23/2026 | 07/27/2026 |
| YERXA BENJAMIN R | SELL | -7,429 | $2.97 | 07/23/2026 | 07/27/2026 |
| Foundation Fighting Blindness Retinal Degeneration Fund | SELL | -1,700,000 | $4.35 | 05/18/2026 | 05/20/2026 |
| Gagnon Robert E. | SELL | -7,842 | $5.18 | 04/23/2026 | 04/27/2026 |
| Jayagopal Ashwath | SELL | -7,542 | $5.19 | 04/23/2026 | 04/27/2026 |
| Magrath George | SELL | -9,511 | $5.22 | 04/23/2026 | 04/27/2026 |
| Zaremba Rabourn Amy | SELL | -1,641 | $5.20 | 04/23/2026 | 04/27/2026 |
| SCHACHLE JOSEPH K | SELL | -4,697 | $5.22 | 04/23/2026 | 04/27/2026 |
| YERXA BENJAMIN R | SELL | -7,470 | $5.24 | 04/23/2026 | 04/27/2026 |
| Ainsworth Sean | BUY | +24,367 | Not reported | 04/20/2026 | 04/22/2026 |
| Bennett Jean | BUY | +24,367 | Not reported | 04/20/2026 | 04/22/2026 |
| Benton Susan | BUY | +24,367 | Not reported | 04/20/2026 | 04/22/2026 |
| Gallagher Cam | BUY | +24,367 | Not reported | 04/20/2026 | 04/22/2026 |
| Graves Adrienne L | BUY | +24,367 | Not reported | 04/20/2026 | 04/22/2026 |
| MANUSO JAMES S J | BUY | +24,367 | Not reported | 04/20/2026 | 04/22/2026 |
| Rodgers Richard J | BUY | +24,367 | Not reported | 04/20/2026 | 04/22/2026 |
| Jayagopal Ashwath | SELL | -3,719 | $5.12 | 03/16/2026 | 03/18/2026 |
| Magrath George | SELL | -24,438 | $5.21 | 03/16/2026 | 03/18/2026 |